An Open-Label, Single-Arm, Multicenter, Study of Telbivudine in Nucleos(t)Ide-naive Subjects of Black/African American or Hispanic/Latino Origin With Compensated Chronic Hepatitis B Virus (HBV) Infection.

Trial Profile

An Open-Label, Single-Arm, Multicenter, Study of Telbivudine in Nucleos(t)Ide-naive Subjects of Black/African American or Hispanic/Latino Origin With Compensated Chronic Hepatitis B Virus (HBV) Infection.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Telbivudine (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 22 Sep 2016 Status changed from discontinued to withdrawn prior to enrolment.
    • 01 Nov 2011 Planned end date changed from 1 Aug 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 01 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top